Fixed-dose combination therapy for the prevention of cardiovascular disease

  • Protocol
  • Intervention

Authors

  • Angharad N de Cates,

    1. Warwick Medical School, University of Warwick, Division of Health Sciences, Coventry, UK
    Search for more papers by this author
  • Matthew RB Farr,

    1. Warwick Medical School, University of Warwick, Division of Health Sciences, Coventry, UK
    Search for more papers by this author
  • Karen Rees,

    1. Warwick Medical School, University of Warwick, Division of Health Sciences, Coventry, UK
    Search for more papers by this author
  • Juan P Casas,

    Corresponding author
    1. London School of Hygiene and Tropical Medicine; Department of Epidemiology and Public Health, University College London, Department of Non-communicable Disease Epidemiology, London, UK
    • Juan P Casas, Department of Non-communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine; Department of Epidemiology and Public Health, University College London, Keppel Street, London, WC1E 7HT, UK. juan.pablo-casas@lshtm.ac.uk.

    Search for more papers by this author
  • Mark Huffman

    1. Northwestern University Feinberg School of Medicine, Departments of Preventative Medicine and Medicine (Cardiology), Chicago, USA
    Search for more papers by this author

Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

To determine the effectiveness of fixed-dose combination therapy on optimising CVD risk factors and reducing CVD fatal and non-fatal events for both primary and secondary prevention of CVD. Details of CVD events and risk factors included are listed in the methods. We will also determine any adverse events associated with taking fixed-dose combination therapy. This will include studies conducted in both developed and developing regions of the world.